MHRA Looks To Triptans, Anti-Hypertensives As Next Switch Categories

The UK's Medicines & Healthcare products Regulatory Agency expects to review an application to reclassify a triptan for migraine from Prescription Only Medicine (POM) to Pharmacy (P) status in the next year and a half